Journal issues > Issue 7, November 2023 > Haematological highlights from ASCO 2023

Haematological highlights from ASCO 2023

SUMMARY

At the ASCO 2023 conference, a dedicated session focused on exploring the most recent advancements in the management of haematological malignancies. CAR therapy brought promising results for acute lymphoblastic leukaemia (ALL), spanning B-ALL with obe-cel and brexu-cel and introducing CD5 CAR-T cells for T-ALL patients. Notably, combining inotuzumab ozogamicin with blinatumomab or DA-EPOCH chemotherapy achieved significant efficacy in ALL patients. Additionally, an observational study underscored the critical importance of treating adolescents and young adults with ALL at specialised cancer centres. In acute myeloid leukaemia (AML), the trifunctional NK cell engager SAR44359 displayed promising anti-leukaemic activity. Finally, luspatercept and the telomerase inhibitor imetelstat boosted transfusion independence and haemoglobin levels in myelodysplastic syndrome patients.

(BELG J HEMATOL 2023;14(7):313–9)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top